Literature DB >> 20537116

Immunization of Bos taurus steers with Babesia bovis recombinant antigens MSA-1, MSA-2c and 12D3.

J Antonio Alvarez1, U Lopez, C Rojas, V M Borgonio, V Sanchez, R Castañeda, P Vargas, J V Figueroa.   

Abstract

The purpose of this research was to evaluate the recombinant proteins MSA-1, MSA-2c and 12D3 as a combined immunogen for cattle. Fifteen steers were randomly assigned into three groups of five animals each (I, II and III). On day 0, cattle in group I were injected with 50 microg each of rMSA-1, rMSA-2c and r12D3 with the adjuvant Montanide 75; cattle in Group II received adjuvant-PBS, and Group III were untreated controls. On day 14, cattle in Group I received a second injection of the three recombinant proteins in adjuvant and cattle in Group II again received adjuvant alone. On day 28, all groups of cattle were challenged with a field strain of Babesia bovis. After challenge, the experimental cattle were clinically and serologically monitored. Three of the five steers immunized with the combined recombinant B. bovis proteins seroconverted on day 14 post-immunization (P.I.) and the maximum titre was 1 : 1600. All five immunized steers presented strong seropositivity to B. bovis antigens at day 21 P.I. The prepatent periods of vaccinated cattle were delayed until day 10 post-challenge exposure versus 8 and 7 days in Groups II and III, respectively. Cattle in all groups had fever above 41 degrees C; the reduction in packed cell volume was not significantly different (P > 0.05) in vaccinated group I compared with Groups II and III (29% versus 26% and 31%, respectively). Treatment was required for one steer in the control group. During the period of the study, the weight of cattle in Groups I and II increased an average of 9 and 7 kg, whereas the weight of the control cattle was reduced on average 4 kg. Immunization with rMSA-1-rMSA-2c-r12D3 proteins was not sufficient to prevent clinical symptoms against challenge, but the immunologic response was sufficient to protect steers against a mild virulent strain of B. bovis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20537116     DOI: 10.1111/j.1865-1682.2010.01117.x

Source DB:  PubMed          Journal:  Transbound Emerg Dis        ISSN: 1865-1674            Impact factor:   5.005


  5 in total

1.  Compilation of parasitic immunogenic proteins from 30 years of published research using machine learning and natural language processing.

Authors:  Stephen J Goodswen; Paul J Kennedy; John T Ellis
Journal:  Sci Rep       Date:  2022-06-20       Impact factor: 4.996

2.  The genetic diversity of merozoite surface antigen 1 (MSA-1) among Babesia bovis detected from cattle populations in Thailand, Brazil and Ghana.

Authors:  Daisuke Nagano; Thillaiampalam Sivakumar; Alane Caine Costa De De Macedo; Tawin Inpankaew; Andy Alhassan; Ikuo Igarashi; Naoaki Yokoyama
Journal:  J Vet Med Sci       Date:  2013-07-12       Impact factor: 1.267

3.  A recombinant multi-antigen vaccine formulation containing Babesia bovis merozoite surface antigens MSA-2a1, MSA-2b and MSA-2c elicits invasion-inhibitory antibodies and IFN-γ producing cells.

Authors:  Alba Marina Gimenez; Katia S Françoso; Jonatan Ersching; Marcelo Y Icimoto; Vitor Oliveira; Anabel E Rodriguez; Leonhard Schnittger; Monica Florin-Christensen; Mauricio M Rodrigues; Irene S Soares
Journal:  Parasit Vectors       Date:  2016-11-14       Impact factor: 3.876

Review 4.  Bovine Babesiosis in Turkey: Impact, Current Gaps, and Opportunities for Intervention.

Authors:  Sezayi Ozubek; Reginaldo G Bastos; Heba F Alzan; Abdullah Inci; Munir Aktas; Carlos E Suarez
Journal:  Pathogens       Date:  2020-12-11

5.  Comparative Study of Indirect Fluorescent Antibody, ELISA, and Immunochromatography Tests for Serological Diagnosis of Bovine Babesiosis Caused by Babesia bovis.

Authors:  José Juan Lira-Amaya; Grecia Martínez-García; R Montserrat Santamaria-Espinosa; Roberto O Castañeda-Arriola; Juan J Ojeda-Carrasco; Guillermina Ávila-Ramírez; Julio V Figueroa-Millán
Journal:  Animals (Basel)       Date:  2021-11-24       Impact factor: 2.752

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.